<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pbio</journal-id><journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id><journal-id journal-id-type="pmc">plosbiol</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Biology</journal-title></journal-title-group><issn pub-type="epub">1545-7885</issn><issn pub-type="ppub">1544-9173</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pbio.0030044</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Cell Biology</subject>
          <subject>Infectious Diseases</subject>
          <subject>Molecular Biology</subject>
          <subject>Virology</subject>
          <subject>Infectious Diseases/HIV Infection and AIDS</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Viruses</subject>
        </subj-group>
      </article-categories><title-group><article-title>HIV-1 Tat Stimulates Transcription Complex Assembly through Recruitment of TBP in the Absence of TAFs</article-title><alt-title alt-title-type="running-head">Tat Promotes Transcription via a TAF-less TBP</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Raha</surname>
            <given-names>Tamal</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Cheng</surname>
            <given-names>S. W. Grace</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Green</surname>
            <given-names>Michael R</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label>
				
				<addr-line>Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America</addr-line>
				
			</aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Kadonaga</surname>
            <given-names>Jim</given-names>
          </name>
          <role>Academic Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">University of California, San Diego, 
				
				
			United States of America</aff><author-notes>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">michael.green@umassmed.edu</email></corresp>
        <fn fn-type="con" id="n1">
          <p> TR and MRG conceived and designed the experiments. TR and SWGC performed the experiments. TR, SWGC, and MRG analyzed the data. TR and SWGC contributed reagents/materials/analysis tools. TR and MRG wrote the paper.</p>
        </fn>
      <fn fn-type="conflict">
        <p> The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>2</month>
        <year>2005</year>
      </pub-date><pub-date pub-type="epub">
        <day>8</day>
        <month>2</month>
        <year>2005</year>
      </pub-date><volume>3</volume><issue>2</issue><elocation-id>e44</elocation-id><history>
        <date date-type="received">
          <day>9</day>
          <month>6</month>
          <year>2004</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>12</month>
          <year>2004</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2005</copyright-year><copyright-holder>Raha et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article page="e76" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pbio.0030076" xlink:title="primer" xlink:type="simple">
				<article-title>A New Paradigm in Eukaryotic Biology: HIV Tat and the Control of Transcriptional Elongation</article-title>
			</related-article><related-article page="e72" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pbio.0030072" xlink:title="synopsis" xlink:type="simple">
				<article-title>An HIV Protein Plays a Surprising Role in Gene Activation</article-title>
			</related-article><abstract>
        <p>The human immunodeficiency virus type I (HIV-1) transactivator protein Tat is an unusual transcriptional activator that is thought to act solely by promoting RNA polymerase II processivity. Here we study the mechanism of Tat action by analyzing transcription complex (TC) assembly in vivo using chromatin immunoprecipitation assays. We find, unexpectedly, that like typical activators Tat dramatically stimulates TC assembly. Surprisingly, however, the TC formed on the HIV-1 long terminal repeat is atypical and contains
					TATA-box-binding protein (TBP) but not TBP-associated factors (TAFs). Tat function involves direct interaction with the cellular cofactor positive transcription elongation factor b (P-TEFb). Artificial tethering of P-TEFb subunits to HIV-1 promoter DNA or nascent RNA indicates that P-TEFb is responsible for directing assembly of a TC containing TBP but not TAFs. On the basis of this finding, we identify P-TEFb-dependent cellular promoters that also recruit TBP in the absence of TAFs. Thus, in mammalian cells transcription of protein-coding genes involves alternative TCs that differ by the presence or absence of TAFs.</p>
      </abstract><abstract abstract-type="toc">
        <p>The transcriptional activator, HIV-1 Tat, not only acts by promoting RNA polymerase processivity, but it is able to promote transcription complex assembly in the absence of
					TATA- box-binding protein-associated factors.</p>
      </abstract></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>In eukaryotes, gene regulation is largely controlled at the transcriptional level. Factors involved in the accurate transcription of eukaryotic structural genes by RNA polymerase II (class II genes) can be classified into two groups. First, general (or basic) transcription factors (GTFs) are necessary and can be sufficient for accurate transcription initiation in vitro (for review, see [<xref ref-type="bibr" rid="pbio-0030044-b01">1</xref>]). Such factors include RNA polymerase II itself and at least six GTFs: TFIID, TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH. The GTFs assemble on the core promoter in an ordered fashion to form a transcription pre-initiation complex (PIC). The first step in PIC assembly is binding of the GTF TFIID to the
				TATA box. TFIID is a multi-subunit complex consisting of the
				TATA-box-binding protein (TBP) and a set of tightly bound TBP-associated factors (TAFs) [<xref ref-type="bibr" rid="pbio-0030044-b02">2</xref>,<xref ref-type="bibr" rid="pbio-0030044-b03">3</xref>,<xref ref-type="bibr" rid="pbio-0030044-b04">4</xref>].
			</p>
      <p>Transcriptional activity is greatly stimulated by the second class of factors, promoter-specific activator proteins (activators). In general, cellular activators are sequence-specific DNA-binding proteins whose recognition sites are usually present in sequences upstream of the core promoter (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b05">5</xref>,<xref ref-type="bibr" rid="pbio-0030044-b06">6</xref>]). In addition to a sequence-specific DNA-binding domain, a typical activator also contains a separable activation domain. A variety of studies indicate that activators work, at least in part, by increasing PIC formation through a mechanism thought to involve direct interactions with one or more components of the transcription machinery [<xref ref-type="bibr" rid="pbio-0030044-b01">1</xref>,<xref ref-type="bibr" rid="pbio-0030044-b07">7</xref>,<xref ref-type="bibr" rid="pbio-0030044-b08">8</xref>,<xref ref-type="bibr" rid="pbio-0030044-b09">9</xref>]. Activators can also act through other mechanisms, such as increasing the rate of transcriptional elongation, promoting multiple rounds of transcription, and directing chromatin modifications (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b10">10</xref>]).</p>
      <p>The Tat protein of human immunodeficiency virus type I (HIV-1) is a potent activator of the viral long terminal repeat (LTR) and is required for viral replication (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b11">11</xref>,<xref ref-type="bibr" rid="pbio-0030044-b12">12</xref>,<xref ref-type="bibr" rid="pbio-0030044-b13">13</xref>]). Unlike typical activators, which bind to promoter DNA, Tat binds to nascent viral RNA through an RNA-binding site termed the TAR element. Tat function involves direct interaction with the cellular cofactor called positive transcription elongation factor b (P-TEFb), which is composed of two subunits, cyclin T1 (CycT1) and CDK9 (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b14">14</xref>,<xref ref-type="bibr" rid="pbio-0030044-b15">15</xref>]). Several lines of evidence have suggested that unlike typical activators, Tat stimulates transcriptional elongation rather than initiation. According to the current model (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b11">11</xref>,<xref ref-type="bibr" rid="pbio-0030044-b12">12</xref>,<xref ref-type="bibr" rid="pbio-0030044-b13">13</xref>]), in the absence of Tat, RNA polymerase II initiates from the HIV-1 LTR in a form unable to elongate efficiently and thus stalls (or pauses) near the transcription start site. When present, Tat binds to TAR and recruits P-TEFb, allowing CDK9 to phosphorylate the C-terminal domain of the RNA polymerase II large subunit, thereby increasing transcriptional processivity.</p>
      <p>The chromatin immunoprecipitation (ChIP) assay has provided a powerful approach to study in vivo the mechanism by which activators stimulate transcription and to delineate the composition of transcription complexes (TCs). In yeast, ChIP analysis has been used to show that activators function, at least in part, by stimulating TC assembly. These studies have also revealed that at certain promoters TBP is recruited in the absence of TAFs [<xref ref-type="bibr" rid="pbio-0030044-b16">16</xref>,<xref ref-type="bibr" rid="pbio-0030044-b17">17</xref>], indicating that, at least in yeast, some TCs contain TBP but not TFIID. Here we perform ChIP experiments to study the mechanism of transcription activation by Tat in vivo.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Experimental Design</title>
        <p>To analyze transcription stimulation by Tat and other activators we performed ChIP experiments in transiently transfected mammalian tissue culture cells. Plasmids expressing a reporter construct, containing a core promoter and various combinations of activator-binding sites, were transiently transfected into HeLa or 293T cells. In some experiments, a second plasmid expressing an activator was co-transfected. Reporter activity or primer extension was used to quantitate transcription levels. TC assembly was analyzed by a ChIP assay using antibodies directed against components of four representative GTFs involved in distinct stages of TC assembly: TFIID (TBP and typically TAF1 and TAF5), TFIIB, mediator (CDK8 and hMed6), and RNA polymerase II (RBP1). In most experiments the analysis was performed using two sets of primers: one set encompassed the core promoter, transcription start site, and immediate downstream region, and a second set was located far downstream of the transcription start site, within the open reading frame (ORF).</p>
      </sec>
      <sec id="s2b">
        <title>Diverse Activators Function by Increasing TC Assembly</title>
        <p>In yeast, it has been shown that activators stimulate TC assembly, which is evident at the earliest step of this process, interaction of TBP with the
					TATA box [<xref ref-type="bibr" rid="pbio-0030044-b18">18</xref>,<xref ref-type="bibr" rid="pbio-0030044-b19">19</xref>]. To confirm that this was also the case in mammalian cells, we used a ChIP assay to analyze TC assembly in three well-characterized model systems: transcription directed by Gal4-VP16, transcription directed by the SV40 enhancer, and transcription directed by the adenovirus (Ad) E1a protein.
				</p>
        <p>The artificial activator Gal4-VP16 contains an unusually potent acidic activation domain and can stimulate transcription in many species and cell types including mammalian tissue culture cells [<xref ref-type="bibr" rid="pbio-0030044-b05">5</xref>]. <xref ref-type="fig" rid="pbio-0030044-g001">Figure 1</xref>A shows, consistent with previous studies, that on a synthetic promoter containing four Gal4-binding sites upstream of the
					TATA box, transcription was not detectable in the absence of Gal4-VP16, whereas addition of Gal4-VP16 led to a large transcriptional increase. The accompanying ChIP assay shows that in the absence of Gal4-VP16 there was no detectable association of GTFs with the promoter. However, addition of Gal4-VP16 led to a large increase in recruitment of all GTFs analyzed, explaining the transcriptional stimulation. Consistent with the transcription results, RNA polymerase II was associated with the ORF in the presence but not absence of Gal4-VP16. Also, as expected, the GTFs were associated with the core promoter and not the ORF.
				</p>
        <fig id="pbio-0030044-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0030044.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Diverse Activators Function by Increasing TC Assembly</title>
            <p>(A) Gal4-VP16. Left: a CAT reporter construct containing the E1b core promoter and four Gal4-binding sites (G4E1bCAT) was transiently trans-fected into 293T cells, together with a plasmid expressing Gal4-VP16. Middle: transcription levels were determined by quantitating CAT reporter activity. Right: TC assembly was analyzed by a ChIP assay using the indicated antibodies. The percentage of DNA immunoprecipitated relative to input is indicated. The location of the primers used in the ChIP assay to analyze the promoter (black) or ORF (gray) is schematically shown on the left.</p>
            <p>(B) SV40 enhancer. Shown on the left is a schematic diagram of a construct containing a minimal rabbit <italic>β</italic>-globin promoter and harboring or lacking the SV40 enhancer. Also shown is transcription analysis by CAT assay (middle) and TC assembly (right) in transiently transfected HeLa cells.</p>
            <p>(C) Ad E1a. Left: a CAT reporter construct containing the Ad E4 promoter and upstream ATF-binding sites (E4CAT) was transiently transfected into HeLa cells, together with a plasmid expressing Ad E1a. Middle: transcription analysis by CAT assay is shown. Right: TC assembly is shown.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0030044.g001" xlink:type="simple"/>
        </fig>
        <p>Transcription of certain genes requires a <italic>cis-</italic>acting enhancer element that is often located at a distance from the transcription start site (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b20">20</xref>]). The enhancer functions by providing binding sites for cellular activators. For example, a minimal <italic>β-globin</italic> promoter is inefficiently expressed, but addition of an appropriate enhancer element dramatically increases transcription [<xref ref-type="bibr" rid="pbio-0030044-b21">21</xref>]. <xref ref-type="fig" rid="pbio-0030044-g001">Figure 1</xref>B shows, as expected, that a minimal rabbit <italic>β-globin</italic> promoter was virtually inactive, whereas transcriptional activity was greatly increased by addition of the SV40 enhancer. The ChIP analysis shows that in the absence of the SV40 enhancer there was no detectable association of GTFs with the <italic>β-globin</italic> promoter. Upon addition of the SV40 enhancer, there was a large increase in GTF recruitment that correlated with the increased transcriptional activity.</p>
        <p>Finally, we analyzed transcription directed by the Ad E1a protein. Efficient transcription from Ad early promoters requires the viral E1a protein as well as the participation of cellular transcription factors that also bind to the promoter (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b22">22</xref>]). For example, the Ad E4 promoter contains multiple binding sites for cellular ATF proteins, which are required for efficient transcription activation by E1a [<xref ref-type="bibr" rid="pbio-0030044-b23">23</xref>]. <xref ref-type="fig" rid="pbio-0030044-g001">Figure 1</xref>C shows, as expected, that in the absence of E1a there was only a background level of Ad E4 transcription, and that E1a increased transcription dramatically. The accompanying ChIP assay shows that in the absence of E1a there was no significant association of GTFs with the promoter, whereas transfection of E1a resulted in recruitment of all GTFs analyzed in a manner that paralleled the increased transcriptional activity.</p>
        <p>In summary, the results of <xref ref-type="fig" rid="pbio-0030044-g001">Figure 1</xref> indicate, as in yeast, that in three well-studied higher eukaryotic examples, transcription activation involves promotion of TC assembly. Moreover, as in yeast, the stimulatory effect is evident at the earliest step of TC assembly, the TBP–
					TATA box interaction.
				</p>
      </sec>
      <sec id="s2c">
        <title>The HIV-1 Tat Protein Stimulates TC Assembly through Recruitment of TBP in the Absence of TAFs</title>
        <p>We next investigated Tat-mediated transcription activation and TC assembly on the HIV-1 LTR promoter. <xref ref-type="fig" rid="pbio-0030044-g002">Figure 2</xref>A shows, as expected, that in the absence of Tat there was no detectable transcription from the HIV-1 LTR, and that addition of Tat increased transcription dramatically. The accompanying ChIP experiment (<xref ref-type="fig" rid="pbio-0030044-g002">Figure 2</xref>A, left) shows that in the absence of Tat, association of GTFs with the core promoter was virtually undetectable. Sp1, a constitutive cellular activator that binds upstream of the HIV-1 core promoter was, as expected, associated with the promoter in the absence of Tat and unaffected by Tat addition (<xref ref-type="fig" rid="pbio-0030044-g002">Figure 2</xref>A, right). Significantly, in the absence of Tat there was no detectable association of RNA polymerase II near the transcription start site or within the ORF (<xref ref-type="fig" rid="pbio-0030044-g002">Figure 2</xref>A, left). However, following addition of Tat, there was a large increase in association of TBP, TFIIB, mediator, and RNA polymerase II with the promoter, which paralleled the transcriptional increase. Also, as expected, there was a large increase in association of RNA polymerase II with the ORF. Following recruitment of P-TEFb to the HIV-1 LTR by Tat, P-TEFb associates with and phosphorylates RNA polymerase II [<xref ref-type="bibr" rid="pbio-0030044-b12">12</xref>,<xref ref-type="bibr" rid="pbio-0030044-b24">24</xref>]. Accordingly, the ChIP assay (<xref ref-type="fig" rid="pbio-0030044-g002">Figure 2</xref>A, right) shows that in the presence of Tat the two P-TEFb subunits, CycT1 and CDK9, were present at both the promoter and the ORF. Unexpectedly, although TBP and the other GTFs were efficiently recruited to the promoter in the presence of Tat, there was no significant recruitment of the two TAFs analyzed, TAF1 or TAF5 (left panel).</p>
        <fig id="pbio-0030044-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0030044.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>The HIV-1 Tat Protein Stimulates TC Assembly through Recruitment of TBP in the Absence of TAFs</title>
            <p>(A) A CAT reporter construct containing the TAR element and Sp1-binding sites ([−83]HIV LTRCAT) was transiently transfected into 293T cells, together with a plasmid expressing Tat. Left: transcription analysis by CAT assay is shown. Middle and right: TC assembly is shown. Bottom: a schematic diagram of the CAT reporter construct is shown.</p>
            <p>(B) TC assembly was monitored in a chronically HIV-1-infected cell line, 8E5/LAV, that harbors an integrated provirus that is constitutively transcribed. Virus production was confirmed by analysis of p24 levels and reverse transcriptase activity in the culture medium (data not shown).</p>
            <p>(C) TC assembly was monitored in the chronically infected cell line U1 on the integrated HIV-1 LTR in the presence or absence of PMA.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0030044.g002" xlink:type="simple"/>
        </fig>
        <p>We note that recruitment of Tat was not observed in the ChIP assay, which detects proteins bound either directly or indirectly to DNA (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b25">25</xref>]). Unlike all the other transcription factors, which associate with the TC through DNA–protein or protein–protein interactions, Tat is bound to nascent RNA [<xref ref-type="bibr" rid="pbio-0030044-b11">11</xref>,<xref ref-type="bibr" rid="pbio-0030044-b12">12</xref>,<xref ref-type="bibr" rid="pbio-0030044-b13">13</xref>].</p>
        <p>To determine whether the lack of TAF recruitment was a general feature of Tat-directed transcription, we analyzed a chronically HIV-1-infected cell line, 8E5/LAV, which harbors an integrated provirus that is constitutively transcribed [<xref ref-type="bibr" rid="pbio-0030044-b26">26</xref>]. <xref ref-type="fig" rid="pbio-0030044-g002">Figure 2</xref>B shows that TBP, TFIIB, mediator, Sp1, P-TEFb, and RNA polymerase II, but not TAF1 or TAF5, were associated with the integrated proviral promoter, consistent with the results of the transient transfection assay.</p>
        <p>We also analyzed a second chronically HIV-1-infected cell line, U1, which has been used as a model to study viral latency. U1 cells harbor an integrated viral genome, but, unlike 8E5/LAV cells, the constitutive level of viral expression is extremely low. Viral expression can be induced by phorbol esters, which stimulate transcription through upstream NF-κB-binding sites in the HIV-1 LTR, leading to Tat synthesis and a subsequent substantial Tat-mediated transcriptional increase [<xref ref-type="bibr" rid="pbio-0030044-b27">27</xref>,<xref ref-type="bibr" rid="pbio-0030044-b28">28</xref>]. Thus, U1 cells provide an experimental system to analyze TC assembly from an integrated HIV-1 LTR in the inactive (−PMA) or active (+PMA) state. <xref ref-type="fig" rid="pbio-0030044-g002">Figure 2</xref>C shows that following activation of the HIV-1 LTR by PMA addition, there was a large increase in recruitment of TBP and RNA polymerase II, whereas TAF1 and TAF5 were once again not detected.</p>
        <p>To investigate further the composition of the TC formed on the HIV-1 LTR, we obtained a panel of antibodies directed against nine additional human TAFs (TAF2, TAF4, TAF6, TAF7, TAF8, TAF9, TAF11, TAF12, and TAF13), as well as antibodies against four subunits of the S
					TAGA complex (PAF65β, hSpt3, hGCN5, and TRRAP) and the TBP-interacting protein Mot1. The results (<xref ref-type="fig" rid="pbio-0030044-g003">Figure 3</xref>A) show that when transcription was directed by Gal4-VP16, all 11 TAFs analyzed were bound to the promoter, as expected for recruitment of TFIID. By contrast, when transcription was directed by Tat, none of the 11 TAFs were recruited to the HIV-1 LTR. Gal4-VP16 also recruited all four S
					TAGA subunits analyzed, none of which were associated with the HIV-1 LTR in the presence of Tat. Finally, Mot1 was not recruited when transcription was directed by either Gal4-VP16 or Tat. On the basis of these data we conclude that the TC formed on the HIV-1 LTR lacks at least 11, and probably all, of the 14 TFIID TAFs. In the experiments presented below, TAF1 and TAF5 were analyzed as representative TAFs.
				</p>
        <fig id="pbio-0030044-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0030044.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>TAFs Are Not Recruited to the HIV 1-LTR and Not Required by Tat for Transcription Activation</title>
            <p>(A) TC assembly was analyzed by a ChIP assay using antibodies directed against nine additional human TAFs, four subunits of the S
							TAGA complex, and Mot1. TAFs that are also present in S
							TAGA are indicated by asterisks. Bottom: schematic diagrams of the promoter constructs are shown.
						</p>
            <p>(B) Transcription analysis in ts13 cells, which harbor a temperature-sensitive mutation in TAF1. Ts13 cells grown at the permissive or non-permissive temperature were transiently transfected with a luciferase reporter plasmid and a plasmid expressing a transcriptional activator. Transcription was monitored by luciferase activity, and normalized relative to activity at the permissive temperature.</p>
            <p>(C) Left: immunoblot analysis is shown. 293A cells were transfected with a TAF5 or TAF12 shRNA expression vector or an empty vector (control) and analyzed by immunoblotting using the indicated antibodies. Right: transcription levels were monitored by luciferase reporter activity in shRNA-treated cells, and normalized relative to luciferase activity in non-shRNA-treated cells.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0030044.g003" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2d">
        <title>TAFs Are Not Required for Tat-Mediated Transcription Activation</title>
        <p>The results of the ChIP experiments strongly suggested that transcription activation by Tat did not require TAFs. To confirm this supposition, we examined the ability of Tat to stimulate transcription following TAF inactivation. First, we examined the ability of Tat to activate transcription in ts13 cells, which harbor a temperature-sensitive mutation in TAF1 [<xref ref-type="bibr" rid="pbio-0030044-b29">29</xref>,<xref ref-type="bibr" rid="pbio-0030044-b30">30</xref>]. <xref ref-type="fig" rid="pbio-0030044-g003">Figure 3</xref>B shows, as expected, that inactivation of TAF1 significantly diminished transcription activation by VP16 and E1a, whereas Tat-mediated transcription activation was unaffected. In a second approach, we used short hairpin RNAs (shRNAs) to knockdown expression of TAF5 or TAF12 in 293A cells. Immunoblot analysis confirmed that shRNA-mediated knockdown of TAF expression was efficient and specific (<xref ref-type="fig" rid="pbio-0030044-g003">Figure 3</xref>C, left). Transcriptional analysis revealed that knockdown of TAF5 or TAF12 substantially decreased transcription directed by VP16, whereas Tat-mediated transcription activation was unaffected (<xref ref-type="fig" rid="pbio-0030044-g003">Figure 3</xref>C, right). (Because 293A cells are transformed by and express E1a, activation by E1a could not be analyzed in this experiment.) Collectively, the results of <xref ref-type="fig" rid="pbio-0030044-g003">Figure 3</xref> demonstrate that TAFs are not involved in transcription activation directed by the HIV-1 Tat protein.</p>
      </sec>
      <sec id="s2e">
        <title>Tat and P-TEFb Direct Recruitment of TBP in the Absence of TAFs</title>
        <p>The results described above indicate that on the HIV-1 LTR transcription activation involves assembly of an atypical TC that contains TBP but not TAFs. However, these experiments do not distinguish whether the critical determinant for recruitment of TBP and not TFIID is Tat or the promoter, the HIV-1 LTR. To address this issue we performed a series of artificial tethering experiments.</p>
        <p>Previous studies have shown that Tat can activate transcription when directed to the HIV-1 LTR through a heterologous DNA-binding domain [<xref ref-type="bibr" rid="pbio-0030044-b31">31</xref>,<xref ref-type="bibr" rid="pbio-0030044-b32">32</xref>,<xref ref-type="bibr" rid="pbio-0030044-b33">33</xref>]. We analyzed TC assembly using an HIV-1 LTR derivative that lacked the TAR element and contained upstream Gal4-binding sites. We first examined the TCs formed on this promoter by three Gal4 fusion proteins: Gal4-VP16, Gal4-E1a, and Gal4-Tat. Consistent with previous studies [<xref ref-type="bibr" rid="pbio-0030044-b32">32</xref>], <xref ref-type="fig" rid="pbio-0030044-g004">Figure 4</xref> shows that all three Gal4 fusion proteins activated transcription from this modified HIV-1 LTR derivative. The accompanying ChIP experiments show that Gal4-VP16 and Gal4-E1a supported assembly of a TC that contained all of the GTFs, including TAF1 and TAF5. By contrast, Gal4-Tat directed assembly of a TC in which the TAFs were present at a level significantly below that of TBP and other GTFs. These results indicate that the activator Tat, and not the HIV-1 LTR promoter, directs the selective recruitment of TBP in the absence of TAFs.</p>
        <fig id="pbio-0030044-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0030044.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Tat and P-TEFb Direct Recruitment of TBP in the Absence of TAFs When Tethered to DNA</title>
            <p>Transcription (left) and TC assembly (right) were examined using an HIV-1 LTR derivative that lacks the TAR element and contains upstream Gal4-binding sites (G6[−83]HIV LTRΔTARCAT; bottom) and a series of Gal4 fusion proteins, as indicated.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0030044.g004" xlink:type="simple"/>
        </fig>
        <p>As discussed above, Tat interacts directly with CycT1, a subunit of the transcription elongation factor P-TEFb. Thus, Tat is an adaptor whose function is to recruit P-TEFb. We therefore considered that P-TEFb was ultimately responsible for the selective recruitment of TBP in the absence of TAFs. To address this possibility, we analyzed transcription activation by the two P-TEFb subunits, CycT1 and CDK9. Consistent with previous results [<xref ref-type="bibr" rid="pbio-0030044-b34">34</xref>,<xref ref-type="bibr" rid="pbio-0030044-b35">35</xref>], both Gal4-CycT1 and Gal4-CDK9 activated transcription. The ChIP analysis indicates that both Gal4-CycT1 and Gal4-CDK9 stimulated assembly of a TC that contained all of the GTFs but lacked TAF1 and TAF5. These results confirm that P-TEFb is responsible for directing selective recruitment of TBP in the absence of TAFs.</p>
        <p>In the experiments shown in <xref ref-type="fig" rid="pbio-0030044-g004">Figure 4</xref>, P-TEFb was tethered to DNA, whereas on the HIV-1 LTR, P-TEFb is normally bound through Tat to nascent RNA. We therefore sought to verify that P-TEFb, when bound to nascent RNA, would also selectively recruit TBP in the absence of TAFs. Previous studies have shown that recruitment of CycT1/P-TEFb to the HIV-1 LTR through a heterologous RNA-binding domain can activate transcription in the absence of Tat [<xref ref-type="bibr" rid="pbio-0030044-b36">36</xref>]. We therefore asked whether such an artificially recruited CycT1/P-TEFb protein would stimulate assembly of a TC that contained TBP but not TAFs. We used a previously characterized HIV-1 LTR derivative [<xref ref-type="bibr" rid="pbio-0030044-b36">36</xref>] in which the TAR element was replaced by a minimal binding site for the HIV-1 Rev protein, and examined the ability of a Rev-Tat or Rev-CycT1 fusion protein to stimulate TC assembly.</p>
        <p><xref ref-type="fig" rid="pbio-0030044-g005">Figure 5</xref> shows that in the absence of a Rev fusion protein, both transcription and GTF recruitment were virtually undetectable. Addition of Rev-Tat or Rev-CycT1 resulted in a large transcriptional increase, as expected from previous studies. Significantly, addition of Rev-Tat or Rev-CycT1 also led to a large increase in recruitment of TBP, TFIIB, mediator, and RNA polymerase II, but not TAF1 or TAF5. Thus, in the absence of Tat, Rev-CycT1 stimulated assembly of a TC that contained TBP but not TAFs.</p>
        <fig id="pbio-0030044-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0030044.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Tat and P-TEFb Direct Recruitment of TBP in the Absence of TAFs When Tethered to RNA</title>
            <p>Transcription (left) and TC assembly (right) were examined using a Rev-Tat or Rev-CycT1 fusion protein and an HIV-1 LTR derivative in which the TAR element was replaced by stem loop IIB (SLIIB), a Rev-protein-binding site (HIV SLIIBCAT; bottom).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0030044.g005" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2f">
        <title>Identification of Cellular Promoters That Recruit TBP in the Absence of TAFs</title>
        <p>P-TEFb is also a cofactor for several cellular activators, the best studied of which is CIITA, a transcription factor involved in the expression of major histocompatibility complex (MHC) class II genes (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b37">37</xref>]). In fact, overexpression of Tat can inhibit transcription of MHC class II genes by competing with CIITA for P-TEFb binding [<xref ref-type="bibr" rid="pbio-0030044-b38">38</xref>,<xref ref-type="bibr" rid="pbio-0030044-b39">39</xref>].</p>
        <p>We therefore tested whether the promoters of MHC class II genes also recruited an atypical TC that contained TBP but not TAFs. We analyzed two MHC class II genes known to use CIITA, <italic>HLA-DM</italic> and <italic>HLA-DR,</italic> and, as a negative control, <italic>GAPDH</italic>. RT-PCR analysis confirmed, as expected, that both <italic>HLA-DM</italic> and <italic>HLA-DR</italic> were expressed in 293T cells (data not shown). The associated ChIP experiment (<xref ref-type="fig" rid="pbio-0030044-g006">Figure 6</xref>) shows that the TCs formed on both <italic>HLA-DM</italic> and <italic>HLA-DR</italic> contained all of the GTFs but lacked significant levels of TAF1 and TAF5. By contrast, the TC formed on <italic>GAPDH</italic> contained all of the GTFs, including TAF1 and TAF5. These results indicate that TBP, and not TFIID, is also selectively recruited to specific cellular promoters and strongly support the conclusion that P-TEFb directs this recruitment.</p>
        <fig id="pbio-0030044-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0030044.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>The Cellular Activator CIITA Directs Recruitment of TBP in the Absence of TAFs</title>
            <p>TC assembly was monitored on the promoters of <italic>HLA-DM</italic> and <italic>HLA-DR,</italic> two MHC class II genes known to use CIITA, and, as a negative control, <italic>GAPDH</italic>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0030044.g006" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>A variety of studies have proposed that Tat promotes transcriptional elongation [<xref ref-type="bibr" rid="pbio-0030044-b11">11</xref>,<xref ref-type="bibr" rid="pbio-0030044-b12">12</xref>,<xref ref-type="bibr" rid="pbio-0030044-b13">13</xref>]. However, the effect of Tat on TC assembly in vivo has not been previously analyzed. In this report, we studied the mechanism of Tat action using ChIP assays and found, unexpectedly, that Tat dramatically stimulates TC assembly on the HIV-1 LTR. Perhaps most surprising, the HIV-1 LTR contains an atypical TC that lacks TFIID and that has not been previously described in mammalian cells. By contrast, transcription activation by Gal4-VP16, the SV40 enhancer, or the Ad E1a protein involves assembly of a TC that contains TFIID. Thus, our results reveal mechanistic similarities between apparently diverse classes of activators and unanticipated differences in the composition of mammalian TCs.</p>
      <p>In an HIV-1-infected cell, a low level of Tat-independent transcription can be elicited by cellular activators, such as Sp1, NF-κB, and NFAT, which are bound to upstream regions of the HIV-1 LTR [<xref ref-type="bibr" rid="pbio-0030044-b12">12</xref>]. Tat is recruited to the vicinity of the promoter by binding to this low level of nascent TAR RNA, where it facilitates subsequent rounds of TC assembly and transcription initiation. Thus, once a threshold level of transcription is achieved, Tat stimulates additional transcription, thereby increasing the number of Tat-binding sites (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b40">40</xref>]). This positive feedback mechanism would ensure that viral transcription rapidly increases or decreases, which may be relevant to the ability of HIV-1 to enter latency and, conversely, to be activated from the latent state.</p>
      <sec id="s3a">
        <title>Tat Stimulates TC Assembly</title>
        <p>Previous studies have provided two principal lines of evidence that Tat functions by stimulating transcription elongation. First, Tat has been found to stimulate elongation in an in vivo nuclear run-off assay [<xref ref-type="bibr" rid="pbio-0030044-b41">41</xref>,<xref ref-type="bibr" rid="pbio-0030044-b42">42</xref>,<xref ref-type="bibr" rid="pbio-0030044-b43">43</xref>,<xref ref-type="bibr" rid="pbio-0030044-b44">44</xref>], and in the absence of Tat, apparent prematurely terminated transcripts have been detected [<xref ref-type="bibr" rid="pbio-0030044-b41">41</xref>,<xref ref-type="bibr" rid="pbio-0030044-b45">45</xref>]. However, these in vivo results are complicated by the presence of a second promoter, the initiator of short transcripts, adjacent to the HIV-1 LTR [<xref ref-type="bibr" rid="pbio-0030044-b46">46</xref>,<xref ref-type="bibr" rid="pbio-0030044-b47">47</xref>]. In our experiments RNA polymerase II was not detected either near or far downstream of the transcription start site in the absence of Tat and thus provided no evidence for a paused (or stalled) RNA polymerase II. Consistent with our ChIP data, nuclear run-off experiments have shown that Tat increases the density of RNA polymerase II 9- to 15-fold within the first 25 nucleotides downstream of the transcription start site [<xref ref-type="bibr" rid="pbio-0030044-b42">42</xref>,<xref ref-type="bibr" rid="pbio-0030044-b43">43</xref>], indicating that Tat also stimulates initiation. A second line of evidence has been derived from in vitro experiments in which Tat was found to enhance elongation but not initiation (see, for example, [<xref ref-type="bibr" rid="pbio-0030044-b48">48</xref>]). However, in vitro transcription experiments may fail to faithfully recapitulate in vivo regulation: for example, under in vitro conditions using naked DNA templates, PIC assembly and initiation may no longer be rate-limiting on the HIV-1 LTR. Consistent with this possibility, the HIV-1 LTR is a relatively strong promoter when analyzed as naked DNA in vitro in the absence of Tat (see, for example, [<xref ref-type="bibr" rid="pbio-0030044-b49">49</xref>]). Moreover, initiation effects would not be observed if the cell-free system did not support multiple rounds of transcription from a single DNA template (see, for example, [<xref ref-type="bibr" rid="pbio-0030044-b50">50</xref>]).</p>
        <p>It is important to emphasize that our ChIP assay only analyzed TC assembly. Thus, our results do not rule out the possibility that in addition to stimulating TC assembly, Tat also promotes transcription elongation. Based upon the results presented here and previous studies (reviewed in [<xref ref-type="bibr" rid="pbio-0030044-b11">11</xref>,<xref ref-type="bibr" rid="pbio-0030044-b12">12</xref>,<xref ref-type="bibr" rid="pbio-0030044-b13">13</xref>]), we believe that Tat stimulates TC assembly, thereby promoting initiation and elongation. This dual mechanism of action may explain why Tat is such a potent activator of transcription.</p>
      </sec>
      <sec id="s3b">
        <title>Tat and P-TEFb Direct Recruitment of TBP in the Absence of TAFs</title>
        <p>We have shown that transcription from the HIV-1 LTR involves TBP but not TFIID. This result was particularly unexpected because in mammalian cells TBP is bound to TAFs extremely tightly and numerous biochemical studies have failed to find free TBP [<xref ref-type="bibr" rid="pbio-0030044-b02">2</xref>,<xref ref-type="bibr" rid="pbio-0030044-b03">3</xref>,<xref ref-type="bibr" rid="pbio-0030044-b04">4</xref>]. None of the 11 TAFs, four S
					TAGA subunits, or Mot1 was present on the HIV-1 LTR, strongly suggesting that free TBP is recruited. However, we cannot exclude the possibility that TBP may be associated with unknown proteins that remain to be identified.
				</p>
        <p>Several considerations rule out the possibility that TFIID is actually present in the TC directed by Tat/P-TEFb but that the TAFs are not detected in the ChIP assay. First, numerous studies have shown ChIP to be a remarkably general and robust assay that has successfully detected a wide variety of activators, general initiation and elongation components, chromatin remodeling factors, and histone variants. Second, in experiments not involving Tat or P-TEFb, TAFs were detected at levels comparable to that of TBP on five different promoters (G4E1bCAT, <italic>β-globin</italic>, E4CAT, G6(−83)HIV LTRΔTARCAT, and <italic>GAPDH</italic>). Third, when TC assembly was directed by Tat or P-TEFb the ChIP assay detected all GTFs analyzed, including TBP, but not TAFs on six different promoters ([−83]HIV LTRCAT, integrated HIV-1/LAV, HIV SLIIBCAT, G6[−83]HIV LTRΔTARCAT, <italic>HLA-DM</italic>, and <italic>HLA-DR</italic>]. Finally, and perhaps most persuasively, on the same promoter the presence or absence of TAFs as monitored by ChIP was dictated solely by the upstream bound Gal4 fusion protein (see <xref ref-type="fig" rid="pbio-0030044-g004">Figure 4</xref>).</p>
        <p>Artificial tethering experiments clearly demonstrate that P-TEFb directs recruitment of TBP in the absence of TAFs. Strongly supporting this conclusion is our identification of cellular promoters for which P-TEFb is a cofactor and whose TC contains TBP but not TAFs. How P-TEFb selectively recruits TBP and not TFIID remains to be determined. It has been previously thought that P-TEFb is purely an elongation factor [<xref ref-type="bibr" rid="pbio-0030044-b14">14</xref>,<xref ref-type="bibr" rid="pbio-0030044-b15">15</xref>]. However, we have shown that when tethered to DNA or nascent RNA, P-TEFb can also stimulate TC assembly and dictate the composition of the TC.</p>
        <p>In yeast, promoters have been grouped into two extreme classes based on their requirement for TAFs [<xref ref-type="bibr" rid="pbio-0030044-b16">16</xref>,<xref ref-type="bibr" rid="pbio-0030044-b17">17</xref>]. TAF-dependent promoters require TAFs for transcription, and on these promoters TBP and TAFs are present at comparable levels. TAF-independent promoters do not require TAFs for activity, and on these promoters TAFs are either absent or present at levels far below that of TBP. These yeast results are strikingly similar to the findings reported here, and taken together these results indicate that in both yeast and mammalian cells, transcription of protein-coding genes involves alternative TCs that differ by the presence or absence of TAFs.</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Materials and Methods</title>
      <sec id="s4a">
        <title/>
        <sec id="s4a1">
          <title>Plasmids</title>
          <p>To generate the G4E1bCAT construct, pDSG39, four Gal4-binding sites were inserted upstream of the E1b
						TATA box and the CAT ORF in the vector pSP72 (Promega, Madison, Wisconsin, United States). The <italic>β-globin</italic> constructs containing (pBS) or lacking (pB/E) the SV40 enhancer were provided by Walter Schaffner; pBS contains a 196-bp SV40 enhancer–containing fragment inserted into a plasmid derived from pB6 [<xref ref-type="bibr" rid="pbio-0030044-b51">51</xref>], which harbors the <italic>β-globin</italic> gene. The E4CAT construct, pE4CAT, was previously described [<xref ref-type="bibr" rid="pbio-0030044-b52">52</xref>]. The pFR-Luc plasmid, containing five Gal4-binding sites upstream of the E1b
						TATA box and the luciferase reporter gene, was obtained from Stratagene (La Jolla, California, United States). The HIV LTR-luciferase construct was previously described [<xref ref-type="bibr" rid="pbio-0030044-b53">53</xref>]. The (−83)HIV LTRCAT and G6(−83)HIV LTRΔTARCAT constructs, were previously described [<xref ref-type="bibr" rid="pbio-0030044-b54">54</xref>]. The HIV SLIIBCAT construct, pHIV/SLIIB/CAT [<xref ref-type="bibr" rid="pbio-0030044-b36">36</xref>], was provided by Bryan Cullen.
					</p>
          <p>Plasmids expressing the Gal4-VP16 fusion protein (pGal4-VP16; [<xref ref-type="bibr" rid="pbio-0030044-b55">55</xref>]), E1a (pSV-E1a; [<xref ref-type="bibr" rid="pbio-0030044-b52">52</xref>]), Tat (CMV-Tat; [<xref ref-type="bibr" rid="pbio-0030044-b56">56</xref>]), and the Gal4-E1a fusion protein (pGal4-E1a; [<xref ref-type="bibr" rid="pbio-0030044-b52">52</xref>]) were previously described. To generate pGal4-Tat, pGal4-CycT1, and pGal4-CDK9, the full-length Tat protein, the hCycT1-containing EcoR1 fragment from phCycT1-Rev [<xref ref-type="bibr" rid="pbio-0030044-b36">36</xref>], or the CDK9-containing EcoR1 fragment from pSG5-CDK9 (a gift from Claude Gazin), respectively, were individually cloned into plasmid pSG424 [<xref ref-type="bibr" rid="pbio-0030044-b55">55</xref>] as an in-frame fusion with the Gal4 DNA-binding domain. Rev fusion-protein plasmids pTAT-Rev and phCycT1-Rev [<xref ref-type="bibr" rid="pbio-0030044-b36">36</xref>] were obtained from Bryan Cullen.</p>
        </sec>
        <sec id="s4a2">
          <title>Antibodies</title>
          <p>The α-Gal4 mouse monoclonal (sc-510), α-CDK8 goat polyclonal (sc-1521), α-CDK9 goat polyclonal (sc-7331), α-CycT1 goat polyclonal (sc-8127), α-Med6 goat polyclonal (sc-9434), α-GCN5 goat polyclonal (sc-6303); α-TRRAP rabbit polyclonal (sc-11411), α-TAF1 mouse monoclonal (sc-735), α-TAF5 mouse monoclonal (sc-743), α-Sp1 rabbit polyclonal (sc-59X), and α-alpha tubulin mouse monoclonal (sc-5268) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, California, United States). The α-RNA polymerase II mouse monoclonal antibody (8WG16) was obtained from BAbCO (Berkeley, California, United States). The α-Tat rabbit antiserum was obtained from the National Institutes of Health AIDS Research and Reference Reagent Program (catalog number 705; [<xref ref-type="bibr" rid="pbio-0030044-b57">57</xref>]). The α-TBP mouse monoclonal antibody (SL30–3-563) was provided by Nouria Hernandez; the α-TAF2, α-TAF4, α-TAF6, α-TAF7, α-TAF8, α-TAF9, α-TAF11, α-TAF12, α-TAF13, and α-hSpt3 rabbit polyclonal antibodies were provided by Robert Roeder; the α-Mot1 rabbit polyclonal antibody was provided by Franklin Pugh; and the α-PAF65β rabbit polyclonal antibody was provided by Yoshihiro Nakatani.</p>
        </sec>
        <sec id="s4a3">
          <title>Transcription</title>
          <p>Transcription was measured either by RT-PCR analysis from total RNA isolated from transfected cells or by chloramphenicol acetyl transferase (CAT) assay [<xref ref-type="bibr" rid="pbio-0030044-b58">58</xref>] using <sup>14</sup>C chloramphenicol followed by thin layer chromatography. Signals were visualized by autoradiography and quantitated using National Institutes of Health Image 1.62 software.</p>
        </sec>
        <sec id="s4a4">
          <title>ChIP assay</title>
          <p>HeLa and 293T cells were transfected with 10 μg of effector plasmids and 5 μg of reporter plasmid using standard CaCl<sub>2</sub> transfection methods [<xref ref-type="bibr" rid="pbio-0030044-b59">59</xref>]. Forty-eight hours after transfection, cells were cross-linked by adding formaldehyde to the medium (1% final concentration) and incubated for 10 min at room temperature. The cross-linking reaction was quenched by adding glycine to a final concentration of 0.125 M and incubating for an additional 10 min at room temperature. Cells were then washed with ice-cold PBS containing protease inhibitors, scraped in the same buffer, and washed in PBS. Cells were then lysed in SDS-lysis buffer (1% SDS, 50 mM Tris-HCl [pH 8.0], 10 mM EDTA, and protease inhibitors), and sonicated at least 6–8 times at output 8 for 10 s, with 2 min incubation on ice in between. Lysates were centrifuged at 15,000 rpm for 15 min at 4 °C; 5% of the lysates were kept as input. Lysates were diluted 10-fold with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl [pH 8.0], 16.7 mM NaCl, and protease inhibitors) and pre-cleared with 80 μl of Protein A Agarose-50% Slurry (Upstate Biotechnology, Lake Placid, New York, United States) for 30 min at 4 °C with constant agitation. The agarose beads were pelleted, and the supernatant was incubated overnight with the primary antibody. To each tube, 50 μl of Salmon Sperm DNA/Protein A Agarose-50% Slurry (Upstate Biotechnology) was added, and the mixture was incubated for 1 h at 4 °C. The agarose beads were pelleted by gentle centrifugation, the supernatant was removed, and the pellet was washed twice with low-salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], and 150 mM NaCl), once with high-salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], and 500 mM NaCl), once with LiCl immune complex wash buffer (0.25 M LiCl, 1% NP40, 1% C<sub>24</sub>H<sub>39</sub>NaO<sub>4</sub>, 1 mM EDTA, and 10 mM Tris-HCl [pH 8.0]), and twice with TE (10 mM Tris-HCl [pH 8.0] and 1 mM EDTA). Chromatin was eluted with freshly prepared elution buffer (1% SDS and 0.1 M CHNaO<sub>3</sub>). After reversal of the cross-links, the samples were treated with proteinase K for 1 h at 45 °C, extracted by phenol/chloroform, and ethanol precipitated. The pellet was resuspended in TE, and PCR was performed. Autoradiograms were scanned and quantitated by the National Institutes of Health ImageJ program. IP DNA was quantitated and presented as the ratio of IP to input. Primer sequences are available upon request.</p>
        </sec>
        <sec id="s4a5">
          <title>TAF inactivation</title>
          <p>For TAF1 inactivation, ts13 cells [<xref ref-type="bibr" rid="pbio-0030044-b60">60</xref>] were initially cultured at the permissive temperature (33 °C), after which one set of 6-well plates was shifted to the non-permissive temperature (39.5 °C) while another set was kept at 33 °C. Sixteen hours later, cells were co-transfected with a plasmid expressing a transcriptional activator (Gal4-VP16, E1a, or Tat) and a luciferase reporter plasmid, and incubated further for 24 h prior to measuring transcription by luciferase assay. For shRNA-mediated inactivation of TAFs, 293A cells were transfected with either pcDNA3 (Invitrogen, Carlsbad, California, United States) or a TAF5 or TAF12 shRNA expression vector (Open Biosystems, Huntsville, Alabama, United States), and 18 h later were co-transfected with effector and reporter plasmids. Transcription activation was monitored by luciferase activity 24 h following transfection.</p>
        </sec>
      </sec>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <sec id="s5a1">
        <title>Accession Numbers</title>
        <p>The LocusLink (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/LocusLink/" xlink:type="simple">http://www.ncbi.nlm.nih.gov/LocusLink/</ext-link>) accession numbers for the genes and gene products discussed in this paper are CDK8 (1024), CDK9 (1025), CIITA (4261), CycT1 (904), <italic>GAPDH</italic> (2597), hGCN5 (2648), <italic>HLA-DM</italic> (3109), <italic>HLA-DR</italic> (3122), hSpt3 (8464), MED6 (10001), Mot1 (9044), PAF65β (27097), RBP1 (5430), TAF1 (6872), TAF11 (6882), TAF12 (6883), TAF13 (6884), TAF2 (6873), TAF4 (6874), TAF5 (6877), TAF6 (6878), TAF7 (6979), TAF8 (129685), TAF9 (6880), Tat (155871), TBP (6908), TFIIB (2959), and TRRAP (8295).</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Robert Roeder, Nouria Hernandez, Yoshihiro Nakatani, and Franklin Pugh for providing antibodies; Claude Gazin, Bryan Cullen, and Walter Schaffner for providing plasmids; Maria Zapp and Ellen Kittler for providing 8E5/LAV and U1 cells and advice; and Sara Evans for editorial assistance. This work was supported in part by an National Institutes of Health grant to MRG. MRG is an investigator of the Howard Hughes Medical Institute.</p>
    </ack>
    
    <ref-list>
      <title>References</title>
      <ref id="pbio-0030044-b01">
        <label>1</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Orphanides</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Lagrange</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Reinberg</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The general transcription factors of RNA polymerase II.</article-title>
          <source>Genes Dev</source>
          <year>1996</year>
          <volume>10</volume>
          <fpage>2657</fpage>
          <lpage>2683</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b02">
        <label>2</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Burley</surname>
              <given-names>SK</given-names>
            </name>
            <name name-style="western">
              <surname>Roeder</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Biochemistry and structural biology of transcription factor IID (TFIID).</article-title>
          <source>Annu Rev Biochem</source>
          <year>1996</year>
          <volume>65</volume>
          <fpage>769</fpage>
          <lpage>799</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b03">
        <label>3</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Albright</surname>
              <given-names>SR</given-names>
            </name>
            <name name-style="western">
              <surname>Tjian</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>TAFs revisited: More data reveal new twists and confirm old ideas.</article-title>
          <source>Gene</source>
          <year>2000</year>
          <volume>242</volume>
          <fpage>1</fpage>
          <lpage>13</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b04">
        <label>4</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>TBP-associated factors (TAFIIs): Multiple, selective transcriptional mediators in common complexes.</article-title>
          <source>Trends Biochem Sci</source>
          <year>2000</year>
          <volume>25</volume>
          <fpage>59</fpage>
          <lpage>63</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b05">
        <label>5</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ptashne</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>How eukaryotic transcriptional activators work.</article-title>
          <source>Nature</source>
          <year>1988</year>
          <volume>335</volume>
          <fpage>683</fpage>
          <lpage>689</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b06">
        <label>6</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ptashne</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Gann</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Activators and targets.</article-title>
          <source>Nature</source>
          <year>1990</year>
          <volume>346</volume>
          <fpage>329</fpage>
          <lpage>331</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b07">
        <label>7</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Roeder</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>The role of general initiation factors in transcription by RNA polymerase II.</article-title>
          <source>Trends Biochem Sci</source>
          <year>1996</year>
          <volume>21</volume>
          <fpage>327</fpage>
          <lpage>335</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b08">
        <label>8</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ptashne</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Gann</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional activation by recruitment.</article-title>
          <source>Nature</source>
          <year>1997</year>
          <volume>386</volume>
          <fpage>569</fpage>
          <lpage>577</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b09">
        <label>9</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names>TI</given-names>
            </name>
            <name name-style="western">
              <surname>Young</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Transcription of eukaryotic protein-coding genes.</article-title>
          <source>Annu Rev Genet</source>
          <year>2000</year>
          <volume>34</volume>
          <fpage>77</fpage>
          <lpage>137</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b10">
        <label>10</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lemon</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Tjian</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Orchestrated response: A symphony of transcription factors for gene control.</article-title>
          <source>Genes Dev</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>2551</fpage>
          <lpage>2569</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b11">
        <label>11</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Garber</surname>
              <given-names>ME</given-names>
            </name>
            <name name-style="western">
              <surname>Jones</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>HIV-1 Tat: Coping with negative elongation factors.</article-title>
          <source>Curr Opin Immunol</source>
          <year>1999</year>
          <volume>11</volume>
          <fpage>460</fpage>
          <lpage>465</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b12">
        <label>12</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Karn</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Tackling Tat.</article-title>
          <source>J Mol Biol</source>
          <year>1999</year>
          <volume>293</volume>
          <fpage>235</fpage>
          <lpage>254</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b13">
        <label>13</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Brigati</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Giacca</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Noonan</surname>
              <given-names>DM</given-names>
            </name>
            <name name-style="western">
              <surname>Albini</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>HIV Tat, its TARgets and the control of viral gene expression.</article-title>
          <source>FEMS Microbiol Lett</source>
          <year>2003</year>
          <volume>220</volume>
          <fpage>57</fpage>
          <lpage>65</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b14">
        <label>14</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Price</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.</article-title>
          <source>Mol Cell Biol</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>2629</fpage>
          <lpage>2634</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b15">
        <label>15</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>De Luca</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>De Falco</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Baldi</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Paggi</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Cyclin T: Three forms for different roles in physiological and pathological functions.</article-title>
          <source>J Cell Physiol</source>
          <year>2003</year>
          <volume>194</volume>
          <fpage>101</fpage>
          <lpage>107</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b16">
        <label>16</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kuras</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Kosa</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Mencia</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Struhl</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>TAF-Containing and TAF-independent forms of transcriptionally active TBP in vivo.</article-title>
          <source>Science</source>
          <year>2000</year>
          <volume>288</volume>
          <fpage>1244</fpage>
          <lpage>1248</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b17">
        <label>17</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names>XY</given-names>
            </name>
            <name name-style="western">
              <surname>Bhaumik</surname>
              <given-names>SR</given-names>
            </name>
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Distinct classes of yeast promoters revealed by differential TAF recruitment.</article-title>
          <source>Science</source>
          <year>2000</year>
          <volume>288</volume>
          <fpage>1242</fpage>
          <lpage>1244</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b18">
        <label>18</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kuras</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Struhl</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Binding of TBP to promoters in vivo is stimulated by activators and requires Pol II holoenzyme.</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>399</volume>
          <fpage>609</fpage>
          <lpage>613</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b19">
        <label>19</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names>XY</given-names>
            </name>
            <name name-style="western">
              <surname>Virbasius</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Zhu</surname>
              <given-names>X</given-names>
            </name>
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Enhancement of TBP binding by activators and general transcription factors.</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>399</volume>
          <fpage>605</fpage>
          <lpage>609</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b20">
        <label>20</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Martin</surname>
              <given-names>DI</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional enhancers—On/off gene regulation as an adaptation to silencing in higher eukaryotic nuclei.</article-title>
          <source>Trends Genet</source>
          <year>2001</year>
          <volume>17</volume>
          <fpage>444</fpage>
          <lpage>448</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b21">
        <label>21</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Banerji</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Rusconi</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Schaffner</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences.</article-title>
          <source>Cell</source>
          <year>1981</year>
          <volume>27</volume>
          <fpage>299</fpage>
          <lpage>308</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b22">
        <label>22</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Berk</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Boyer</surname>
              <given-names>TG</given-names>
            </name>
            <name name-style="western">
              <surname>Kapanidis</surname>
              <given-names>AN</given-names>
            </name>
            <name name-style="western">
              <surname>Ebright</surname>
              <given-names>RH</given-names>
            </name>
            <name name-style="western">
              <surname>Kobayashi</surname>
              <given-names>NN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mechanisms of viral activators.</article-title>
          <source>Cold Spring Harb Symp Quant Biol</source>
          <year>1998</year>
          <volume>63</volume>
          <fpage>243</fpage>
          <lpage>252</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b23">
        <label>23</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names>KA</given-names>
            </name>
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>A cellular transcription factor E4F1 interacts with an E1a-inducible enhancer and mediates constitutive enhancer function in vitro.</article-title>
          <source>EMBO J</source>
          <year>1987</year>
          <volume>6</volume>
          <fpage>1345</fpage>
          <lpage>1353</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b24">
        <label>24</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Zhou</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Deng</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Kashanchi</surname>
              <given-names>F</given-names>
            </name>
            <name name-style="western">
              <surname>Brady</surname>
              <given-names>JN</given-names>
            </name>
            <name name-style="western">
              <surname>Shatkin</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2003</year>
          <volume>100</volume>
          <fpage>12666</fpage>
          <lpage>12671</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b25">
        <label>25</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kuo</surname>
              <given-names>MH</given-names>
            </name>
            <name name-style="western">
              <surname>Allis</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment.</article-title>
          <source>Methods</source>
          <year>1999</year>
          <volume>19</volume>
          <fpage>425</fpage>
          <lpage>433</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b26">
        <label>26</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Folks</surname>
              <given-names>TM</given-names>
            </name>
            <name name-style="western">
              <surname>Powell</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Lightfoote</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Koenig</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Fauci</surname>
              <given-names>AS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biological and biochemical characterization of a cloned Leu-3− cell surviving infection with the acquired immune deficiency syndrome retrovirus.</article-title>
          <source>J Exp Med</source>
          <year>1986</year>
          <volume>164</volume>
          <fpage>280</fpage>
          <lpage>290</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b27">
        <label>27</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Folks</surname>
              <given-names>TM</given-names>
            </name>
            <name name-style="western">
              <surname>Justement</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Kinter</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Dinarello</surname>
              <given-names>CA</given-names>
            </name>
            <name name-style="western">
              <surname>Fauci</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line.</article-title>
          <source>Science</source>
          <year>1987</year>
          <volume>238</volume>
          <fpage>800</fpage>
          <lpage>802</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b28">
        <label>28</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Pomerantz</surname>
              <given-names>RJ</given-names>
            </name>
            <name name-style="western">
              <surname>Trono</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Feinberg</surname>
              <given-names>MB</given-names>
            </name>
            <name name-style="western">
              <surname>Baltimore</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency.</article-title>
          <source>Cell</source>
          <year>1990</year>
          <volume>61</volume>
          <fpage>1271</fpage>
          <lpage>1276</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b29">
        <label>29</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hisatake</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Hasegawa</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Takada</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Nakatani</surname>
              <given-names>Y</given-names>
            </name>
            <name name-style="western">
              <surname>Horikoshi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The p250 subunit of native
						TATA box-binding factor TFIID is the cell-cycle regulatory protein CCG1.</article-title>
          <source>Nature</source>
          <year>1993</year>
          <volume>362</volume>
          <fpage>179</fpage>
          <lpage>181</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b30">
        <label>30</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ruppert</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Wang</surname>
              <given-names>EH</given-names>
            </name>
            <name name-style="western">
              <surname>Tjian</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Cloning and expression of human TAFII250: A TBP-associated factor implicated in cell-cycle regulation.</article-title>
          <source>Nature</source>
          <year>1993</year>
          <volume>362</volume>
          <fpage>175</fpage>
          <lpage>179</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b31">
        <label>31</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kamine</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Subramanian</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Chinnadurai</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1991</year>
          <volume>88</volume>
          <fpage>8510</fpage>
          <lpage>8514</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b32">
        <label>32</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Southgate</surname>
              <given-names>CD</given-names>
            </name>
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Delineating minimal protein domains and promoter elements for transcriptional activation by lentivirus Tat proteins.</article-title>
          <source>J Virol</source>
          <year>1995</year>
          <volume>69</volume>
          <fpage>2605</fpage>
          <lpage>2610</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b33">
        <label>33</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Roebuck</surname>
              <given-names>KA</given-names>
            </name>
            <name name-style="western">
              <surname>Rabbi</surname>
              <given-names>MF</given-names>
            </name>
            <name name-style="western">
              <surname>Kagnoff</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>HIV-1 Tat protein can transactivate a heterologous
						TATAA element independent of viral promoter sequences and the <italic>trans</italic>-activation response element.</article-title>
          <source>AIDS</source>
          <year>1997</year>
          <volume>11</volume>
          <fpage>139</fpage>
          <lpage>146</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b34">
        <label>34</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Majello</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Napolitano</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Giordano</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Lania</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo.</article-title>
          <source>Oncogene</source>
          <year>1999</year>
          <volume>18</volume>
          <fpage>4598</fpage>
          <lpage>4605</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b35">
        <label>35</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Taube</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Lin</surname>
              <given-names>X</given-names>
            </name>
            <name name-style="western">
              <surname>Irwin</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Fujinaga</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Peterlin</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes.</article-title>
          <source>Mol Cell Biol</source>
          <year>2002</year>
          <volume>22</volume>
          <fpage>321</fpage>
          <lpage>331</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b36">
        <label>36</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Bieniasz</surname>
              <given-names>PD</given-names>
            </name>
            <name name-style="western">
              <surname>Grdina</surname>
              <given-names>TA</given-names>
            </name>
            <name name-style="western">
              <surname>Bogerd</surname>
              <given-names>HP</given-names>
            </name>
            <name name-style="western">
              <surname>Cullen</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>7791</fpage>
          <lpage>7796</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b37">
        <label>37</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Fontes</surname>
              <given-names>JD</given-names>
            </name>
            <name name-style="western">
              <surname>Kanazawa</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Nekrep</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Peterlin</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>The class II transactivator CIITA is a transcriptional integrator.</article-title>
          <source>Microbes Infect</source>
          <year>1999</year>
          <volume>1</volume>
          <fpage>863</fpage>
          <lpage>869</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b38">
        <label>38</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kanazawa</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Okamoto</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Peterlin</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection.</article-title>
          <source>Immunity</source>
          <year>2000</year>
          <volume>12</volume>
          <fpage>61</fpage>
          <lpage>70</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b39">
        <label>39</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Accolla</surname>
              <given-names>RS</given-names>
            </name>
            <name name-style="western">
              <surname>Mazza</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>De Lerma Barbaro</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>De Maria</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Tosi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication.</article-title>
          <source>Eur J Immunol</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>2783</fpage>
          <lpage>2791</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b40">
        <label>40</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sharp</surname>
              <given-names>PA</given-names>
            </name>
            <name name-style="western">
              <surname>Marciniak</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>HIV TAR: An RNA enhancer?</article-title>
          <source>Cell</source>
          <year>1989</year>
          <volume>59</volume>
          <fpage>229</fpage>
          <lpage>230</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b41">
        <label>41</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kao</surname>
              <given-names>SY</given-names>
            </name>
            <name name-style="western">
              <surname>Calman</surname>
              <given-names>AF</given-names>
            </name>
            <name name-style="western">
              <surname>Luciw</surname>
              <given-names>PA</given-names>
            </name>
            <name name-style="western">
              <surname>Peterlin</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.</article-title>
          <source>Nature</source>
          <year>1987</year>
          <volume>330</volume>
          <fpage>489</fpage>
          <lpage>493</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b42">
        <label>42</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Laspia</surname>
              <given-names>MF</given-names>
            </name>
            <name name-style="western">
              <surname>Rice</surname>
              <given-names>AP</given-names>
            </name>
            <name name-style="western">
              <surname>Mathews</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation.</article-title>
          <source>Cell</source>
          <year>1989</year>
          <volume>59</volume>
          <fpage>283</fpage>
          <lpage>292</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b43">
        <label>43</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Laspia</surname>
              <given-names>MF</given-names>
            </name>
            <name name-style="western">
              <surname>Rice</surname>
              <given-names>AP</given-names>
            </name>
            <name name-style="western">
              <surname>Mathews</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation.</article-title>
          <source>Genes Dev</source>
          <year>1990</year>
          <volume>4</volume>
          <fpage>2397</fpage>
          <lpage>2408</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b44">
        <label>44</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Feinberg</surname>
              <given-names>MB</given-names>
            </name>
            <name name-style="western">
              <surname>Baltimore</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Frankel</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1991</year>
          <volume>88</volume>
          <fpage>4045</fpage>
          <lpage>4049</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b45">
        <label>45</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Palangat</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Meier</surname>
              <given-names>TI</given-names>
            </name>
            <name name-style="western">
              <surname>Keene</surname>
              <given-names>RG</given-names>
            </name>
            <name name-style="western">
              <surname>Landick</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional pausing at +62 of the HIV-1 nascent RNA modulates formation of the TAR RNA structure.</article-title>
          <source>Mol Cell</source>
          <year>1998</year>
          <volume>1</volume>
          <fpage>1033</fpage>
          <lpage>1042</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b46">
        <label>46</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ratnasabapathy</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Sheldon</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Johal</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Hernandez</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters.</article-title>
          <source>Genes Dev</source>
          <year>1990</year>
          <volume>4</volume>
          <fpage>2061</fpage>
          <lpage>2074</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b47">
        <label>47</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Pessler</surname>
              <given-names>F</given-names>
            </name>
            <name name-style="western">
              <surname>Hernandez</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-beta-D-benzimidazole-resistant short transcripts in vitro.</article-title>
          <source>J Biol Chem</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>5375</fpage>
          <lpage>5384</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b48">
        <label>48</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Marciniak</surname>
              <given-names>RA</given-names>
            </name>
            <name name-style="western">
              <surname>Calnan</surname>
              <given-names>BJ</given-names>
            </name>
            <name name-style="western">
              <surname>Frankel</surname>
              <given-names>AD</given-names>
            </name>
            <name name-style="western">
              <surname>Sharp</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>HIV-1 Tat protein <italic>trans</italic>-activates transcription in vitro.</article-title>
          <source>Cell</source>
          <year>1990</year>
          <volume>63</volume>
          <fpage>791</fpage>
          <lpage>802</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b49">
        <label>49</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Parada</surname>
              <given-names>CA</given-names>
            </name>
            <name name-style="western">
              <surname>Roeder</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain.</article-title>
          <source>Nature</source>
          <year>1996</year>
          <volume>384</volume>
          <fpage>375</fpage>
          <lpage>378</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b50">
        <label>50</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hai</surname>
              <given-names>TW</given-names>
            </name>
            <name name-style="western">
              <surname>Horikoshi</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Roeder</surname>
              <given-names>RG</given-names>
            </name>
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Analysis of the role of the transcription factor ATF in the assembly of a functional preinitiation complex.</article-title>
          <source>Cell</source>
          <year>1988</year>
          <volume>54</volume>
          <fpage>1043</fpage>
          <lpage>1051</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b51">
        <label>51</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>de Villiers</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Olson</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Tyndall</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Schaffner</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional ‘enhancers' from SV40 and polyoma virus show a cell type preference.</article-title>
          <source>Nucleic Acids Res</source>
          <year>1982</year>
          <volume>10</volume>
          <fpage>7965</fpage>
          <lpage>7976</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b52">
        <label>52</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lillie</surname>
              <given-names>JW</given-names>
            </name>
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Transcription activation by the adenovirus E1a protein.</article-title>
          <source>Nature</source>
          <year>1989</year>
          <volume>338</volume>
          <fpage>39</fpage>
          <lpage>44</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b53">
        <label>53</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Gazin</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>ZFX transactivation of the HIV-1 LTR is cell specific and depends on core enhancer and
						TATA box sequences.</article-title>
          <source>Nucleic Acids Res</source>
          <year>1999</year>
          <volume>27</volume>
          <fpage>2156</fpage>
          <lpage>2164</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b54">
        <label>54</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Southgate</surname>
              <given-names>CD</given-names>
            </name>
            <name name-style="western">
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: Implications for Tat function.</article-title>
          <source>Genes Dev</source>
          <year>1991</year>
          <volume>5</volume>
          <fpage>2496</fpage>
          <lpage>2507</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b55">
        <label>55</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sadowski</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Triezenberg</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Ptashne</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>GAL4-VP16 is an unusually potent transcriptional activator.</article-title>
          <source>Nature</source>
          <year>1988</year>
          <volume>335</volume>
          <fpage>563</fpage>
          <lpage>564</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b56">
        <label>56</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Cullen</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.</article-title>
          <source>Cell</source>
          <year>1986</year>
          <volume>46</volume>
          <fpage>973</fpage>
          <lpage>982</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b57">
        <label>57</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hauber</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Perkins</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Heimer</surname>
              <given-names>EP</given-names>
            </name>
            <name name-style="western">
              <surname>Cullen</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1987</year>
          <volume>84</volume>
          <fpage>6364</fpage>
          <lpage>6368</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b58">
        <label>58</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Cullen</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>Use of eukaryotic expression technology in the functional analysis of cloned genes.</article-title>
          <source>Methods Enzymol</source>
          <year>1987</year>
          <volume>152</volume>
          <fpage>684</fpage>
          <lpage>704</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b59">
        <label>59</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Chen</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Okayama</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>High-efficiency transformation of mammalian cells by plasmid DNA.</article-title>
          <source>Mol Cell Biol</source>
          <year>1987</year>
          <volume>7</volume>
          <fpage>2745</fpage>
          <lpage>2752</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio-0030044-b60">
        <label>60</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Talavera</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Basilico</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Temperature sensitive mutants of BHK cells affected in cell cycle progression.</article-title>
          <source>J Cell Physiol</source>
          <year>1977</year>
          <volume>92</volume>
          <fpage>425</fpage>
          <lpage>436</lpage>
        </nlm-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>Ad</term>
          <def>
            <p>adenovirus</p>
          </def>
        </def-item>
        <def-item>
          <term>ChIP</term>
          <def>
            <p>chromatin immunoprecipitation</p>
          </def>
        </def-item>
        <def-item>
          <term>CycT1</term>
          <def>
            <p>cyclin T1</p>
          </def>
        </def-item>
        <def-item>
          <term>GTF</term>
          <def>
            <p>general transcription factor</p>
          </def>
        </def-item>
        <def-item>
          <term>HIV-1</term>
          <def>
            <p>human immunodeficiency virus type I</p>
          </def>
        </def-item>
        <def-item>
          <term>LTR</term>
          <def>
            <p>long terminal repeat</p>
          </def>
        </def-item>
        <def-item>
          <term>MHC</term>
          <def>
            <p>major histocompatibility complex</p>
          </def>
        </def-item>
        <def-item>
          <term>ORF</term>
          <def>
            <p>open reading frame</p>
          </def>
        </def-item>
        <def-item>
          <term>PIC</term>
          <def>
            <p>pre-initiation complex</p>
          </def>
        </def-item>
        <def-item>
          <term>P-TEFb</term>
          <def>
            <p>positive transcription elongation factor b</p>
          </def>
        </def-item>
        <def-item>
          <term>shRNA</term>
          <def>
            <p>short hairpin RNA</p>
          </def>
        </def-item>
        <def-item>
          <term>TAF</term>
          <def>
            <p>
							TATA-box-binding protein associated factor
						</p>
          </def>
        </def-item>
        <def-item>
          <term>TBP</term>
          <def>
            <p>
							TATA-box-binding protein
						</p>
          </def>
        </def-item>
        <def-item>
          <term>TC</term>
          <def>
            <p>transcription complex</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>